Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia

In chronic lymphocytic leukemia (CLL), the detection of minimal residual disease (MRD) correlates with outcome in the trial setting. However, MRD assessment does not guide routine clinical management and its assessment remains complex. We incorporated detection of the B cell, tumor-specific antigen...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Cancer J
Hlavní autoři: Farren, T W, Giustiniani, J, Fanous, M, Liu, F, Macey, M G, Wright, F, Prentice, A, Nathwani, A, Agrawal, S G
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2015
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4314455/
https://ncbi.nlm.nih.gov/pubmed/25615279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2014.92
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky